Bayer to present new clinical data on heart and kidney disease treatments

Bayer is reshaping the landscape of modern medicine with its new focus on "precision cardiology."

At the recent European Society of Cardiology Congress 2026, Bayer highlighted significant progress with its flagship drug, finerenone (KERENDIA).

Data from the FIND-CKD trial and the large-scale INFINITY analysis demonstrated that finerenone effectively reduces the risk of kidney failure and cardiovascular events, such as heart failure hospitalizations, across diverse patient groups.

Beyond finerenone, Bayer is broadening its portfolio to include innovative tools like PET radiotracers for cardiac amyloidosis and ongoing research into stroke prevention.

By collaborating with institutions like Vanderbilt University Medical Center, Bayer aims to accelerate the discovery of therapies that intervene early to protect patient health.

As the medical community shifts toward holistic, CKM-focused care, Bayer’s strategic developments reflect a critical evolution in how we manage chronic disease, prioritizing long-term prevention over simple symptom management.